AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. They are also selectively active in the areas of autoimmunity, neuroscience and infection. They build their own capabilities by collaborating with world-renowned scientists and academic institutions, and partner with like-minded, science-led companies. AstraZeneca Australia, have been working to deliver the best value to patients for more than 60 years, and they push the boundaries of science to deliver life-changing medicines..
On-demand webinar: COPD and cardiovascular risk: The deadly duo
Chronic obstructive pulmonary disease (COPD) is a highly symptomatic condition with physical and emotional impacts that greatly reduce quality of life and increase mortality risk.1 Cardiovascular events are common in people with COPD, and are an important cause of morbidity and mortality in the weeks following an acute COPD exacerbation.2,3
Live webinar - COPD and cardiovascular risk: The deadly duo - 17 April 2024
In this webinar GP Conjoint A/Prof Chee Khoo and Conjoint A/Prof Belinda Cochrane review latest recommendations for COPD management and describe the actions you can take to reduce the impact of comorbid cardiovascular risk in patients with COPD.
Clinical audit: Managing the deadly duo of COPD and cardiovascular risk
In this clinical audit, you will identify patients with COPD who have a history of moderate to severe exacerbations in the past 12 months and an increased risk of cardiovascular events. You will consider how your patient’s self-management behaviours, inhaled COPD medications and prescribed non-pharmacological treatments could be further optimised, in line with evidence-based guidelines, to improve symptom control and reduce the risk of further exacerbations.
